Michelle Duong1, Chris Delcher2, Patricia R Freeman2, April M Young3,4, Hannah L F Cooper5. 1. Department of Epidemiology, Emory University, Atlanta, Georgia, USA. 2. Department of Pharmacy Practice & Science, University of Kentucky, Institute for Pharmaceutical Outcomes and Policy, Lexington, Kentucky, USA. 3. Department of Epidemiology, University of Kentucky, Lexington, Kentucky, USA. 4. Center on Drug and Alcohol Research, University of Kentucky, Lexington, Kentucky, USA. 5. Department of Behavioral, Social and Health Education Sciences, Emory University, Atlanta, Georgia, USA.
Abstract
PURPOSE: Rural areas of the United States have experienced outbreaks of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections among people who use drugs (PWUD). Pharmacy-based interventions may play a crucial role in prevention and entry into care, especially when traditional health care access is limited. The willingness of rural PWUD to use pharmacies for HIV/HCV-related services remains unknown. The purpose of this study was to describe the factors associated with the perceived likelihood of participating in free pharmacy-based HIV and HCV testing among PWUD living in rural Kentucky. METHODS: Baseline data from the CARE2HOPE study in five Appalachian counties in eastern Kentucky were used. Participants were recruited using respondent-driven sampling and completed interviewer-administered surveys. Guided by the Andersen and Newman Framework of Health Services Utilization, we examined distributions and correlates of items regarding willingness to participate in free pharmacy-based HIV/HCV testing using logistic regression. Analyses included individuals who reported being HIV (N = 304) or HCV (N = 185) negative. FINDINGS: Seventy-five percent of PWUD reported being "very likely" to participate in free pharmacy-based HIV testing and 80% for HCV testing. Two factors were associated with being less willing to participate in free HIV testing: PWUD who previously tested for HIV (OR: 0.47, CI: 0.25-0.88) and PWUD who obtained a high school diploma or equivalent compared to those who completed less (OR: 0.50, CI: 0.26-0.99). CONCLUSION: Free pharmacy-based HIV and HCV testing was invariably acceptable among most of the rural PWUD in our sample, suggesting that pharmacies might be acceptable testing venues for this population.
PURPOSE: Rural areas of the United States have experienced outbreaks of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections among people who use drugs (PWUD). Pharmacy-based interventions may play a crucial role in prevention and entry into care, especially when traditional health care access is limited. The willingness of rural PWUD to use pharmacies for HIV/HCV-related services remains unknown. The purpose of this study was to describe the factors associated with the perceived likelihood of participating in free pharmacy-based HIV and HCV testing among PWUD living in rural Kentucky. METHODS: Baseline data from the CARE2HOPE study in five Appalachian counties in eastern Kentucky were used. Participants were recruited using respondent-driven sampling and completed interviewer-administered surveys. Guided by the Andersen and Newman Framework of Health Services Utilization, we examined distributions and correlates of items regarding willingness to participate in free pharmacy-based HIV/HCV testing using logistic regression. Analyses included individuals who reported being HIV (N = 304) or HCV (N = 185) negative. FINDINGS: Seventy-five percent of PWUD reported being "very likely" to participate in free pharmacy-based HIV testing and 80% for HCV testing. Two factors were associated with being less willing to participate in free HIV testing: PWUD who previously tested for HIV (OR: 0.47, CI: 0.25-0.88) and PWUD who obtained a high school diploma or equivalent compared to those who completed less (OR: 0.50, CI: 0.26-0.99). CONCLUSION: Free pharmacy-based HIV and HCV testing was invariably acceptable among most of the rural PWUD in our sample, suggesting that pharmacies might be acceptable testing venues for this population.
Authors: Hannah L F Cooper; Brian H Bossak; Barbara Tempalski; Samuel R Friedman; Don C Des Jarlais Journal: J Urban Health Date: 2009-11 Impact factor: 3.671
Authors: Michelle M Van Handel; Charles E Rose; Elaine J Hallisey; Jessica L Kolling; Jon E Zibbell; Brian Lewis; Michele K Bohm; Christopher M Jones; Barry E Flanagan; Azfar-E-Alam Siddiqi; Kashif Iqbal; Andrew L Dent; Jonathan H Mermin; Eugene McCray; John W Ward; John T Brooks Journal: J Acquir Immune Defic Syndr Date: 2016-11-01 Impact factor: 3.731
Authors: Paul J Weidle; Shirley Lecher; Linda W Botts; LaDawna Jones; David H Spach; Jorge Alvarez; Rhondette Jones; Vasavi Thomas Journal: J Am Pharm Assoc (2003) Date: 2014 Sep-Oct
Authors: D C Des Jarlais; H Hagan; S R Friedman; P Friedmann; D Goldberg; M Frischer; S Green; K Tunving; B Ljungberg; A Wodak Journal: JAMA Date: 1995-10-18 Impact factor: 56.272